Yahoo!

Friday December 9, 7:00 am ET

- Anticipate 2006 Earnings of $3.10 to $3.20 Per Share, Representing Top-Tier Pharma Growth

- 2005 Earnings Expected to be at High End of Company's Guidance Range

- No Major Patent Expirations Expected Through This Decade

- Nearly Tripled Product Portfolio with an Unprecedented 9 New Product Launches in 4 Years, Along With 9 New Indications and Line Extensions

- Newer Products Driving Growth; Anticipated to be Nearly One-Quarter of 2006 Revenue

- Increased Productivity 15% in 2005 and Steady Increases Expected Going Forward; Six Sigma Significant Contributor

- Rich Pipeline Result of One of the Most Productive R&D Organizations and Industry-Leading Partnering Capabilities as Ranked by Biotech Companies

- Late-Stage Pipeline Includes 5 High-Potential Products with Submissions Expected Over Next 4 Years, Plus a Number of New Indications and Line Extensions

- Company's Capabilities in Both Biotech Large Molecule and Traditional Small Molecule Combine for Key Competitive Advantage

- Anticipate Near-Term U.S. Submissions of Arxxant for Diabetic Retinopathy and Cymbalta for Generalized Anxiety Disorder; Recently Submitted Byetta for Type 2 Diabetes in Europe and Cialis for ED in Japan